GammaTile Brachytherapy Demonstrates Superior Local Control in Recurrent Brain Metastases
GammaTile achieved 87% local control at 1 year in recurrent brain metastases with 8% toxicity, outperforming historical controls.
Brain Tumors
Latest Post
FDA Approves Modeyso as First Treatment for H3 K27M-Mutant Diffuse Midline Glioma
Modeyso, the first treatment option for this ultra-rare and aggressive brain tumor, is commercially available...
Efficacy and Safety of Dordaviprone (ONC201) in Prospective Clinical Trials of Adult and Pediatric Recurrent H3 K27M-Mutant Diffuse Glioma Patients
Dordaviprone shows 16.7% response rate in adults with recurrent H3 K27M gliomas, with durable responses...
